Peptide Approaches to Opioid Use Disorder: The Research
Opioid Peptide Biology
70,000+ deaths/year
From opioid overdose in the United States alone. Current treatments (methadone, buprenorphine, naltrexone) leave most patients undertreated. Peptide-based approaches target the biology from new angles.
CDC National Vital Statistics, 2024
CDC National Vital Statistics, 2024
View as imageEvery approved medication for opioid use disorder (OUD) works through the same target: the mu-opioid receptor. Methadone activates it (full agonist). Buprenorphine partially activates it (partial agonist). Naltrexone blocks it (antagonist). All three reduce opioid use and overdose death, but retention rates are poor, relapse is common, and the fundamental neurobiology of addiction extends far beyond a single receptor. The brain's endogenous opioid system involves four peptide families (endorphins, enkephalins, dynorphins, nociceptin) acting across four receptor types (mu, delta, kappa, NOP). Peptide-based research is exploring whether modulating this broader system, rather than hammering mu alone, could produce better outcomes. Separately, GLP-1 receptor agonists are showing unexpected anti-opioid effects that have nothing to do with opioid receptors at all. For the underlying biology of how addiction hijacks these peptide systems, see Dynorphin and the Kappa Receptor: The "Dark Side" of Opioid Peptides.
Key Takeaways
- Dual enkephalinase inhibitors (DENKIs) boost endogenous enkephalin levels at the site of pain, producing analgesia without the addiction risk of exogenous opioids[4]
- Nociceptin/orphanin FQ suppresses dopamine release in the nucleus accumbens, counteracting the reward signal that drives opioid seeking[2]
- The A118G polymorphism in the mu-opioid receptor gene alters beta-endorphin binding, potentially explaining individual vulnerability to opioid addiction[3]
- GLP-1 receptor agonists reduced opioid-related outcomes in a real-world analysis of patients with OUD[10]
- A randomized, placebo-controlled trial of semaglutide for treatment-refractory OUD is underway[9]
- Endogenous opioid peptide dysregulation in chronic opioid users persists long after drug cessation, contributing to protracted withdrawal and relapse[7]
The Endogenous Opioid System: Four Peptide Families
The brain produces its own opioids. These endogenous opioid peptides regulate pain, reward, stress, and mood through four receptor types:
Beta-endorphin (31 amino acids, derived from proopiomelanocortin) acts primarily at mu-opioid receptors. It is released during exercise, social bonding, and pleasurable experiences. It drives the "natural high" and is the primary endogenous peptide involved in reward.
Enkephalins (met-enkephalin and leu-enkephalin, 5 amino acids each) act at delta and mu receptors. They are released locally at sites of pain and inflammation, providing endogenous analgesia. Their very short half-life (minutes) limits their duration of action.
Dynorphins (derived from prodynorphin) act primarily at kappa-opioid receptors. Unlike the other families, kappa activation produces dysphoria, aversion, and stress. Dynorphin/kappa signaling opposes the rewarding effects of mu activation and is implicated in the negative emotional states of withdrawal.
Nociceptin/orphanin FQ (17 amino acids) acts at the NOP receptor. It modulates pain processing, stress, and reward in complex ways that often oppose classical opioid actions.[2]
Exogenous opioids (heroin, fentanyl, oxycodone) overwhelm this system by flooding mu receptors with supraphysiological stimulation, producing euphoria far exceeding anything endogenous peptides generate. Chronic use downregulates endogenous peptide production and receptor expression, creating a state where normal pleasures no longer register and cessation produces severe dysphoria.
Enkephalinase Inhibitors: Boosting the Body's Own Painkillers
If the goal is analgesia without addiction, one approach is to amplify the body's own enkephalins rather than introducing exogenous opioids. Enkephalins are rapidly degraded by two enzymes: aminopeptidase N (APN) and neutral endopeptidase (NEP). Inhibiting both enzymes simultaneously with dual enkephalinase inhibitors (DENKIs) increases enkephalin concentrations at the site where they are naturally released.
Szymaszkiewicz and colleagues (2019) reviewed enkephalinase inhibitors as potential therapeutics, noting that DENKIs produce analgesia in animal models without the tolerance, dependence, or respiratory depression characteristic of exogenous opioids.[4]
The theoretical advantage is anatomical specificity. Endogenous enkephalins are released at specific sites (pain pathways, gut) in response to specific stimuli. Blocking their degradation amplifies a signal that is already targeted, unlike systemic opioid administration that activates receptors everywhere. This could provide pain relief for OUD patients who need analgesia without the reward circuit activation that triggers relapse.
DENKIs remain in preclinical and early clinical development. The challenge is achieving sufficient enzyme inhibition at the target site without off-target effects from elevated enkephalin levels in other tissues.
Nociceptin: The Anti-Reward Peptide
Nociceptin/orphanin FQ (N/OFQ) is functionally distinct from classical opioid peptides. Murphy (1996) showed that intracerebroventricular nociceptin suppressed dopamine release in the nucleus accumbens, the brain's primary reward center.[2] This is the opposite of what mu-opioid activation does: where heroin increases dopamine and produces euphoria, nociceptin decreases dopamine and blunts reward.
This makes the NOP receptor system a potential target for reducing opioid reward without blocking mu receptors (which is what naltrexone does, often at the cost of anhedonia and poor treatment adherence).
Ploj and colleagues (2000) demonstrated that alcohol altered nociceptin, dynorphin, and enkephalin levels in mouse brain, establishing that substance use disrupts the broader endogenous opioid peptide network, not just the mu system.[5]
NOP receptor agonists are being developed for anxiety and pain indications. Their potential for OUD is theoretical but grounded in solid neuropharmacology: reducing the reward signal from opioid use without the aversive effects of mu blockade.
Genetic Variation in Opioid Peptide Signaling
Not everyone who uses opioids becomes addicted. Genetic variation in the endogenous opioid system partly explains individual vulnerability.
Bond and colleagues (1998) identified the A118G single-nucleotide polymorphism in the mu-opioid receptor gene (OPRM1) and showed it altered beta-endorphin binding affinity and receptor signaling. Carriers of the 118G variant have reduced mu-receptor function, which has been associated with altered opioid reward, different analgesic requirements, and variable response to naltrexone treatment.[3]
Ban and colleagues (2020) reviewed how altered endogenous neurotransmitter systems, including opioid peptides, contribute to both chronic pain vulnerability and susceptibility to opioid addiction, framing the opioid crisis as partly a consequence of disrupted innate pain-relieving peptide systems.[6]
Understanding these genetic and peptide-level differences could enable personalized OUD treatment: selecting mu agonist, partial agonist, or antagonist therapy based on a patient's OPRM1 genotype and endogenous opioid peptide profile.
Endogenous Opioid Dysregulation in Chronic Use
Chronic opioid use fundamentally alters the endogenous opioid system, and these changes persist long after drug cessation.
Higginbotham and colleagues (2022) reviewed alterations in endogenous opioid systems in both chronic pain and OUD, documenting reduced beta-endorphin production, altered enkephalin release dynamics, and upregulated dynorphin/kappa signaling that persists during abstinence.[7]
Margolis and colleagues (2023) reviewed the spatiotemporal dynamics of endogenous opioid peptides in alcohol use disorder and found that similar disruptions occur across substances of abuse: reduced "feel-good" peptides (endorphins, enkephalins) and elevated "feel-bad" peptides (dynorphins) that drive negative emotional states during withdrawal and abstinence.[8]
This dysregulation explains protracted withdrawal: even after the acute physical symptoms resolve, the endogenous reward system remains impaired for months to years. Patients in early recovery experience anhedonia, dysphoria, and heightened stress reactivity because their natural opioid peptide system has not recovered. This is the biological substrate of relapse. For how beta-endorphin specifically mediates the initial reward response, see Beta-Endorphin and the Reward Pathway: Where Addiction Begins.
GLP-1 Receptor Agonists: An Unexpected Entry
The most surprising development in OUD research comes from metabolic peptides. GLP-1 receptor agonists, developed for diabetes and obesity, appear to reduce opioid use and opioid-related outcomes through mechanisms independent of opioid receptors.
Au and colleagues (2025) systematically reviewed GLP-1 receptor agonists for OUD treatment and found consistent signals across preclinical and observational data suggesting reduced opioid reward, decreased drug-seeking behavior, and lower overdose rates in patients taking GLP-1 drugs for metabolic indications.[11]
Qeadan and colleagues (2025) analyzed real-world prescription data and found that patients with OUD who were prescribed GLP-1 or GIP/GLP-1 receptor agonists for metabolic conditions had improved substance-related outcomes compared to matched controls not receiving these drugs.[10]
Freet and colleagues (2025) published the protocol for a randomized, double-blind, placebo-controlled trial of semaglutide in treatment-refractory OUD, the first rigorous prospective test of a GLP-1 agonist specifically for opioid addiction.[9]
Bronson and colleagues (2025) reviewed the potential mechanisms, including GLP-1 receptor modulation of mesolimbic dopamine signaling, reduction of neuroinflammation, and restoration of reward circuit homeostasis.[11]
The GLP-1 approach is conceptually different from everything else in OUD treatment: rather than targeting the opioid system directly, it modulates the reward circuitry upstream, potentially reducing the drive to use any substance. For the broader picture of GLP-1 effects on addictive behavior, see Endogenous Opioid Peptides and Addiction: How Your Brain Gets Hijacked.
Where Peptide OUD Research Is Heading
The current pipeline of peptide-based OUD strategies addresses different aspects of the disorder:
| Approach | Target | Stage | Mechanism |
|---|---|---|---|
| DENKIs | APN + NEP enzymes | Preclinical/early clinical | Boost endogenous enkephalins for pain without addiction |
| NOP agonists | Nociceptin receptor | Preclinical | Reduce reward signaling in nucleus accumbens |
| Fentanyl vaccines | Fentanyl molecules | Phase 1 (2025) | Antibody sequestration prevents brain entry |
| GLP-1 agonists | GLP-1R in reward circuits | RCT protocol published | Modulate dopamine, reduce drug-seeking |
| Kappa antagonists | Kappa-opioid receptor | Preclinical | Block dynorphin-driven dysphoria in withdrawal |
Combination strategies that address both the reward (mu/beta-endorphin) and aversion (kappa/dynorphin) systems, while modulating upstream reward circuits (GLP-1), represent the most comprehensive approach. The endogenous opioid system evolved as an integrated network; treating OUD may require intervening at multiple nodes simultaneously.
The Bottom Line
Peptide-based approaches to opioid use disorder go beyond the mu-opioid receptor that all current medications target. Dual enkephalinase inhibitors aim to boost endogenous enkephalins for pain relief without addiction risk. Nociceptin system modulation could reduce opioid reward without the aversive effects of mu blockade. Genetic variation in beta-endorphin/mu-receptor interactions explains individual vulnerability. GLP-1 receptor agonists are the most clinically advanced new approach, with a randomized trial of semaglutide for treatment-refractory OUD underway. The endogenous opioid peptide system's disruption during chronic use and its slow recovery during abstinence remain central to understanding why relapse rates are so high.